Theorem Clinical Research

Articles Published in 2012

AMRI closes Bothell site, integrates in vitro services with drug discovery

Monday, December 3, 2012 09:58 AM

As the next step in its Smartsourcing strategy, AMRI, a global contract research and manufacturing organization, has taken further actions to expand and better integrate its in vitro biology services with its total drug discovery service platform.

More... »

Quest Diagnostics

Nobel Prize winner Bruce Beutler joins Sound Pharma

Monday, December 3, 2012 09:32 AM

Sound Pharmaceuticals, a privately held biopharmaceutical company with a focus on developing drugs for hearing loss and brain injury, has appointed Bruce A. Beutler as a scientific advisor.

More... »


The CenterWatch Monthly, December 2012

Monday, December 3, 2012 09:00 AM

Publicity, regulation tightening reins on use of KOLs

More... »

BioCryst, Presidio mutually terminate merger

Friday, November 30, 2012 01:50 PM

BioCryst Pharmaceuticals, a biopharmaceutical company focused on infectious and inflammatory diseases, and privately held Presidio Pharmaceuticals, a San Francisco-based clinical stage specialty pharmaceutical company focused on small molecule antiviral therapeutics, have agreed to the mutual termination of their Merger Agreement and the related Investor Financing Agreement entered into on October 17, 2012.

More... »

Boston Scientific enrolls first patient in coronary stent study featuring bioabsorbable polymer coating

Friday, November 30, 2012 12:13 PM

The first patient has been enrolled in Boston Scientific’s EVOLVE II clinical trial, designed to further assess the safety and effectiveness of the SYNERGY Stent System and support FDA and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.  

More... »

Ampio Pharmaceuticals names Disbrow as COO

Friday, November 30, 2012 11:45 AM

Ampio Pharmaceuticals, a Greenwood Village, Colo.-based biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, has appointed Josh Disbrow as chief operating officer.

More... »

Common canine virus may lead to new vaccines for deadly human diseases

Friday, November 30, 2012 11:21 AM

Researchers at the University of Georgia have discovered that a virus commonly found in dogs may serve as the foundation for the next great breakthrough in human vaccine development.

More... »

Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

Friday, November 30, 2012 10:55 AM

Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

More... »

Rib-X Pharmaceuticals closes first tranche in $67.5M financing

Friday, November 30, 2012 10:28 AM

Rib-X Pharmaceuticals, a New Haven, Conn.-based biopharmaceutical company developing new antibiotics to treat serious and life-threatening infections, has closed the first tranche of a $67.5 million Series 2 preferred stock financing. A second tranche is anticipated to close around the end of 2012.

More... »

Aptiv Solutions opens new office

Thursday, November 29, 2012 01:52 PM

Reston, Va.-based Aptiv Solutions, a biopharmaceutical and medical device development services company with a focus on adaptive clinical trial design, simulation and execution, opened a new office in Durham, N.C., combining offices with its subsidiary Trio Clinical Resourcing.

More... »

`

CWWeekly

March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs